Table 2.
The prevalence of HIV, HCV, HBV and their co-infections among PWID and FSWs by regions of the World Health Organization (WHO); 2008–2018.
| Prevalence | Americas, % (95% CI) |
Africa, % (95% CI) |
South-East Asia, % (95% CI) |
Europe, % (95% CI) |
Eastern Mediterranean, % (95% CI) |
Western Pacific, % (95% CI) |
Total, % (95% CI) |
|---|---|---|---|---|---|---|---|
| PWID | |||||||
| HIV | 10 (7–14) |
24 (16–34) |
22 (16–28) |
12 (6–20) |
8 (3–13) |
11 (2–26) |
15 (12–18) |
| HCV | 64 (51–77) |
38 (10–72) |
54 (43–66) |
59 (53–65) |
60 (46–73) |
75 (68–82) |
60 (55–64) |
| HBV | 3 (1–6) |
5 (2–9) |
9 (7–11) |
3 (1–5) |
5 (4–6) |
- | 6 (5–8) |
| HIV/HCV | 9 (3–18) |
16 (11–22) |
17 (11–24) |
16 (16–28) |
8 (4–14) |
- | 13 (9–18) |
| HIV/HBV | - | 1 (1–3) |
2 (1–5) |
- | 1 (0–2) |
- | 2 (1–3) |
| HBV/HCV | - | - | 3 (1–6) |
- | 3 (2–5) |
- | 3 (1–5) |
| HIV/HCV/HBV | - | 1 (0–2) |
2 (1–4) |
- | 1 (0–2) |
- | 2 (1–3) |
| FSWs | |||||||
| HIV | 4 (2–9) |
19 (8–34) |
18 (10–27) |
- | 0 (0–0) |
1 (0–1) |
5 (4–5) |
| HCV | 1 (0–2) |
9 (0–29) |
3 (0–8) |
- | 2 (0–5) |
1 (1–1) |
1 (1–2) |
| HBV | 1 (0–1) |
5 (1–10) |
4 (2–7) |
- | 1 (0–6) |
- | 3 (1–5) |
| HIV/HCV | 0 (0–0) |
23 (18–27) |
1 (0–6) |
- | - | - | 3 (0–9) |
| HIV/HBV | - | 7 (5–10) |
1 (0–2) |
- | - | - | 1 (0–3) |